Hims & Hers rises on FDA move towards loosening restrictions on peptides

Hims & Hers Health

16/04/2026 10:19

** Shares of telehealth firm Hims & Hers Health HIMS.N rise 8.7% to $26.39 premarket

** On Wednesday, the US FDA said it will convene a panel of outside experts to consider allowing production of seven popular peptides which are currently restricted over safety concerns

** The committee will discuss whether compounders should be allowed to manufacture peptides such as BPC-157 and TB-500 for purposes for ulcerative colitis and wound healing

     ** "The FDA's plans to more clearly define the regulatory status of several peptides is an important step toward moving these treatments out of the gray market, and into more trusted channels overseen by vetted healthcare professionals," HIMS' chief medical officer said in a statement

** Up to last close, stock down 25.2% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))